Literature DB >> 31271632

Special Tuberculosis Treatment Information System (SITE-TB) in Brazil: background, description and perspectives.

Patricia Bartholomay1, Rejane Sobrino Pinheiro2, Daniele Maria Pelissari3, Denise Arakaki-Sanchez3, Fernanda Dockhorn3, Jorge Luiz Rocha4, Estefania Quilma Andrade de Araújo Penna3, Draurio Barreira5, Wildo Navegantes de Araújo1, Margareth Dalcolmo4.   

Abstract

The Special Tuberculosis Treatment Information System (SITE-TB) arose mainly from the need to routinely monitor all persons with drug-resistant tuberculosis (DR-TB) in Brazil, as well as to qualify tuberculosis' drug control. Developed by the Professor Hélio Fraga Reference Center and the Management Sciences for Health/Brazil Project, this online system was implemented in 2013 in all Brazilian states. In addition to DR-TB, the system registers people with drug-sensitive tuberculosis with special regimen indications, and those with nontuberculous mycobacterial infections identified by differential diagnosis of tuberculosis. All confirmed tuberculosis cases should be notified on the Notifiable Diseases Information System (SINAN). In situations where treatment with special regimens is necessary, the case is closed on SINAN and notified on SITE-TB. Professionals from tuberculosis reference centers report and monitor these cases on the system, as well as manage tuberculosis' drugs.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31271632     DOI: 10.5123/S1679-49742019000200002

Source DB:  PubMed          Journal:  Epidemiol Serv Saude        ISSN: 1679-4974


  1 in total

1.  Laboratory-based study of drug resistance and genotypic profile of multidrug-resistant tuberculosis isolates in Salvador, Bahia, Brazil.

Authors:  Erivelton de Oliveira Sousa; Rita Terezinha de Oliveira Carneiro; Fátima Cristina Onofre Fandinho Montes; Emilyn Costa Conceição; Patricia Bartholomay; Jamocyr Moura Marinho; Karla Valéria Batista Lima; Marcio Santos da Natividade; Wildo Navegantes de Araújo; Eliana Dias Matos; Theolis Barbosa
Journal:  Rev Soc Bras Med Trop       Date:  2022-07-25       Impact factor: 2.141

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.